BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 32039725)

  • 1. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
    Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
    BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
    Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
    Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
    Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
    Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
    Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
    BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
    Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
    Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
    Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
    Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
    Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
    Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.